Search Within

Shanu Modi

  1. "Department of Medicine"
Formats
  1. Meeting Abstract (150)
  2. Journal Article (99)
  3. Review (11)
  4. Correspondence (2)
  5. Editorial (2)
  6. Research Letter (1)
Groups
  1. Breast Medicine Service (265)
  2. Department of Medicine (265)
  3. Solid Tumor Oncology Division (265)
  4. Survivorship Research (113)
  5. GSK Faculty (104)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (88)

More Groups

People
  1. Clifford Hudis (79)
  2. Larry Norton (53)
  3. Sarat Chandarlapaty (49)
  4. Sujata Patil (44)
  5. Chau Dang (41)
  6. Komal Jhaveri (34)

More People

Years
  1. 2025 (5)
  2. 2024 (23)
  3. 2023 (15)
  4. 2022 (19)
  5. 2021 (19)
  6. 2020 (21)

More Years

Publications
  1. Journal of Clinical Oncology (65)
  2. Cancer Research (50)
  3. Annals of Oncology (27)
  4. Breast Cancer Research and Treatment (14)
  5. Clinical Cancer Research (10)
  6. Clinical Breast Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (66)
  2. American Association for Cancer Research (64)
  3. Oxford University Press (33)
  4. Elsevier Inc. (19)
  5. Springer (18)
  6. Nature Publishing Group (13)

More Publishers

Results (265)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation
    Journal Article

    Rodina, A.; Xu, C.; Digwal, C. S.; Joshi, S.; Patel, Y.; Santhaseela, A. R.; Bay, S.; Merugu, S.; Alam, A.; Yan, P.; more...
    Nature Communications (2023)

    Fulltext@MSK | Save
  • ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
    Review

    Tarantino, P.; Viale, G.; Press, M. F.; Hu, X.; Penault-Llorca, F.; Bardia, A.; Batistatou, A.; Burstein, H. J.; Carey, L. A.; Cortes, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Targeting HER2-low in metastatic breast cancer: An evolving treatment paradigm
    Review

    Yang, C.; Brezden-Masley, C.; Joy, A. A.; Sehdev, S.; Modi, S.; Simmons, C.; Henning, J. W.
    Therapeutic Advances in Medical Oncology (2023)

    Fulltext@MSK | Save
  • Statin therapy enhances the efficacy of HER2 directed antibody-drug conjugates in breast cancer
    Meeting Abstract

    Liu, B.; Drago, J. Z.; Rao, Y.; Pereira, P. R.; Safonov, A.; Marra, A.; Ahmed, M. S.; Modi, S.; Reis, J. S.; Montemurro, F.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study
    Meeting Abstract

    Modi, S.; Jacot, W.; Yamashita, T.; Sohn, J.; Vidal, M.; Tokunaga, E.; Tsurutani, J.; Ueno, N. T.; Chae, Y. S.; Lee, K. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Multifocal, durable and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan
    Meeting Abstract

    Tosi, U.; Moss, N.; Santomasso, B.; Beal, K.; Modi, S.
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • ACE-Breast-03: A phase II study patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens treated with ARX788
    Meeting Abstract

    Hurvitz, S. A.; Kalinsky, K.; Tripathy, D.; Sledge, G.; Gradishar, W. J.; O'Shaughnessy, J.; Modi, S.; Park, H.; McCartney, A.; Frentzas, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
    Meeting Abstract

    Ueno, N. T.; Jacot, W.; Yamashita, T.; Sohn, J.; Tokunaga, E.; Prat, A.; Tsurutani, J.; Park, Y. H.; Rugo, H. S.; Xu, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: A DESTINY-Breast01 subgroup analysis
    Journal Article

    Jerusalem, G.; Park, Y. H.; Yamashita, T.; Hurvitz, S. A.; Modi, S.; Andre, F.; Krop, I. E.; FarreĢ, X. G.; You, B.; Saura, C.; more...
    Cancer Discovery (2022)

    Fulltext@MSK | Save
  • Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens
    Meeting Abstract

    Lu, J. M.; Kalinsky, K.; Tripathy, D.; Sledge, G. W.; Gradishar, W. J.; O'Regan, R.; O'Shaughnessy, J.; Modi, S.; Park, H.; McCartney, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save